TMEM167A

Across TCGA pan-cancer cohorts, TMEM167A RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated TMEM167A data layer compared with 1 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher TMEM167A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM167A expression acts as an unfavorable survival marker, although some lineages such as PRAD and MESO show a favorable association.

KIRP, STAD, and KICH are the cancer types where TMEM167A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	III,IV	0.134	0.622	.001	53	view →
STAD	DFS	Quartile	IV	0.261	0.860	.004	39	view →
KICH	DFS	Median	All	0.671	1.000	.004	38	view →
UVM	OS	Median	III,IV	0.281	1.000	.003	38	view →
OV	DFS	Tertile	III,IV	0.478	0.583	.007	34	view →
LIHC	DFS	Quartile	All	0.405	0.597	<.001	34	view →
HNSC	OS	Quartile	All	0.592	0.852	.008	24	view →
CESC	DFS	Tertile	III,IV	0.553	0.848	.025	18	view →
PRAD	DFS	Tertile	All	0.967	0.911	.001	18	view →
SCLC	DFS	Median	IV	0.137	0.559	.008	17	view →
MESO	OS	Quartile	III,IV	0.842	0.419	.017	15	view →
LGG	OS	Tertile	All	0.749	0.950	<.001	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

TMEM167A–KIRP (DFS)

Open the KIRP breakdown →